Related Experiment Video
Updated: Sep 11, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
Published on: April 12, 2021
Personalized Medication for Chronic Diseases Using Multimodal Data-Driven Chain-of-Decisions
Xiaoli Chu1, Yiheng Ye2, Siqiao Tang3
1State Key Laboratory of Traditional Chinese Medicine Syndrome/Big Data Research Center of Chinese Medicine, The 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, 510120, China.
None:
The precise matching of medication regimens to individual patients, known as personalized medication, is critical for the effective management of chronic diseases. Traditional machine learning-based models for personalized medication regimens typically rely solely on either clinical macro-phenotypes or molecular-level drug characteristics. It remains challenging to capture the patient-medication relationship from a comprehensive perspective that integrates individual patient characteristics with macro- and micro-level properties of the medication. Determining patient-medication relationships constitutes a three-stage sequential decision process from a clinical decision-making perspective. Therefore, inspired by Chain-of-Thought prompting, which simulates the decision-making process of human experts, a Multimodal Data-Driven Chain-of-Decisions (MDD-CoD) framework is proposed, where three-stage deep learning tasks are sequentially organized to reflect upstream-downstream logical dependencies, thereby forming a coherent clinical decision-making process. The model incorporates multimodal clinical phenotype data, multi-attribute medication data, and insights from clinical experts. Performance evaluation of the model involved comprehensive experiments utilizing five datasets covering four chronic diseases sourced from three hospitals. The dataset comprises information from chronic kidney disease (CKD), membranous nephropathy (MN), rheumatoid arthritis (RA), colorectal cancer (CRC), and knee osteoarthritis (KOA), totaling 3173 unimodal, 502 multimodal, and 2187 medication records from 3675 patients. Experimental results demonstrate that the framework achieves enhanced predictive performance in personalized medication decision-making based on individual patient disease characteristics, surpassing the strongest baseline across all tasks. This framework serves as a foundational model for clinical mixed data, with improved generalization and interpretability in cross-disease personalized decision-making tasks. It offers a scalable solution for the implementation of personalized medication regimens for chronic diseases.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Analysis of Population Pharmacokinetic Data
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

